CD274 and cervical carcinoma: In recent years, anti-PD-1/PD-L1 checkpoint blockade immunotherapy (CBI) has been approved to treat metastatic squamous cell carcinomas, including head and neck squamous cell carcinoma, lung cancer, and cervical cancer (Lyu et al., 2020).